On BarChart recently I screened for the stocks trading above 100,000 shares a day that were hitting the most new highs, eliminating stocks trading below $5 and those that scored below 80% buy on BarChart's technical indicators.

 

I came up with a stock I'd never heard of -- Cytori Therapeutics (CYTX). As I researched it, I found that it is involved with finding cell-based medical therapies. But instead of using embryonic stem cells, it uses fat cells.

 

Plenty of us have plenty of those, and fat cell research might not run into the ethical debate that other stem cell research is receiving.

The stock has hit 14 new highs in the past 20 trading sessions and hit new highs in four of the past five sessions. Price appreciation in the past 65 days has been 100%, and BarChart's technical indicators are hitting 13 out of 13 "buy" signals for a 100% buy rating.

On Wall Street, the five analysts following the stock have four buy recommendations and one underperform rating (which hasn't changed since January 2008.) The analysts' consensus for sales growth is 17.7% with EPS growth of 54.5% expected next year.

I always try to see what some of the other sites think about a stock in case I missed some negative signals. On Wall Street Survivor, Mark's checklist has a Survivor Sentiment rating of 5 of 5, a fundamental rating of 5 of 5 and a technical rating of 5 of 5. The Motley Fool CAPS members think the stock will outperform the market 132 to 20 with the All Stars giving it a 34 to 9 vote. The Wall Street guys Motley Fool follows vote 4 to 0.

This stock passes the three tests I use: